CCM
ELDN icon

Catalio Capital Management’s Eledon Pharmaceuticals ELDN Stock Holding History

Catalio Capital Management’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.05M Buy
1,639,816
+379,996
+30% +$895K 1.06% 28
2025
Q4 		$1.9M Buy
1,259,820
+198,688
+19% +$472K 0.34% 38
2025
Q3 		$2.75M Buy
+1,061,132
New +$3.1M 0.51% 30

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $712M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
ZP
Zimmer Partners New York $4.15B AUM 14.2% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Catalio Capital Management's ELDN Position: Q1 2026 in Review

Catalio Capital Management increased its Eledon Pharmaceuticals (ELDN) stake by 30% in Q1 2026, buying an estimated $895K and bringing the position to 1,639,816 shares worth $5.05M. The position accounts for 1.06% of the portfolio, ranked #28.

Catalio Capital Management first reported a position in ELDN in Q3 2025 and has held it in 3 quarters since. 121 funds tracked by Wall St. Rank hold ELDN as of Q1 2026.

  • Catalio Capital Management held 1,639,816 shares of Eledon Pharmaceuticals worth $5.05M as of Q1 2026.
  • Catalio Capital Management bought 379,996 Eledon Pharmaceuticals shares in Q1 2026, an estimated $895K.
  • Eledon Pharmaceuticals made up 1.06% of Catalio Capital Management's portfolio in Q1 2026, its #28 holding.
  • Catalio Capital Management first reported a position in Eledon Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • 121 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q1 2026.

Based on Catalio Capital Management's 13F filing for Q1 2026, filed 15 May 2026.